C9085 — Injection, avalglucosidase alfa-ngpt, 4 mg
C9085 is a HCPCS Level II code for injection, avalglucosidase alfa-ngpt, 4 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on March 31, 2022 and is not valid on new claims.
This code has been terminated
CMS terminated C9085 on March 31, 2022. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9085
- Long descriptor
- Injection, avalglucosidase alfa-ngpt, 4 mg
- Short descriptor
- Inj avalglucosid alfa-ngpt
- Added
- January 1, 2022
- Terminated
- March 31, 2022
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9085
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9085 is not quite right, the correct code is very often within a few positions of it.
- C9077Injection, cabotegravir and rilpivirine, 2mg/3mgterminated
- C9078Injection, trilaciclib, 1 mgterminated
- C9079Injection, evinacumab-dgnb, 5 mgterminated
- C9080Injection, melphalan flufenamide hydrochloride, 1 mgterminated
- C9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9082Injection, dostarlimab-gxly, 100 mgterminated
- C9083Injection, amivantamab-vmjw, 10 mgterminated
- C9084Injection, loncastuximab tesirine-lpyl, 0.1 mgterminated
- C9086Injection, anifrolumab-fnia, 1 mgterminated
- C9087Injection, cyclophosphamide, (auromedics), 10 mgterminated
- C9088Instillation, bupivacaine and meloxicam, 1 mg/0.03 mgterminated
- C9089Bupivacaine, collagen-matrix implant, 1 mgterminated
- C9090Injection, plasminogen, human-tvmh, 1 mgterminated
- C9091Injection, sirolimus protein-bound particles, 1 mgterminated
- C9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mgterminated
- C9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mgterminated
Questions about C9085
What is HCPCS code C9085?
C9085 is a HCPCS Level II code for injection, avalglucosidase alfa-ngpt, 4 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9085?
The CMS HCPCS file marks C9085 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9085 still valid?
No. C9085 was terminated on March 31, 2022 and should not be used on new claims.